Sumatriptan Succinate Patents

Given below is the list of patents protecting Sumatriptan Succinate, along with the drug name that holds that patent and the company name owning that drug.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sumatriptan Succinate's patents.

Latest Legal Activities on Sumatriptan Succinate's Patents

Given below is the list recent legal activities going on the following patents of Sumatriptan Succinate.

Activity	Date	Patent Number
Today's Legal Activities
Expire Patent Critical	10 Jun, 2024	US9327114
Email Notification Critical	24 Apr, 2024	US10537554
Email Notification Critical	24 Apr, 2024	US11364224
Change in Power of Attorney (May Include Associate POA) Critical	24 Apr, 2024	US11364224
Change in Power of Attorney (May Include Associate POA) Critical	24 Apr, 2024	US10537554
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27	15 Apr, 2024	US10537554
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27	15 Apr, 2024	US11364224
Maintenance Fee Reminder Mailed Critical	25 Dec, 2023	US9327114
Payment of Maintenance Fee, 4th Year, Large Entity	21 Jul, 2023	US10537554
Expire Patent Critical	24 Apr, 2023	US8983594

Sumatriptan Succinate's Family Patents

Full family tree